Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Bioengineering a pre-vascularized pouch for subsequent islet transplantation using VEGF-loaded polylactide capsules

N. Kasoju, A. Pátíková, E. Wawrzynska, A. Vojtíšková, T. Sedlačík, M. Kumorek, O. Pop-Georgievski, E. Sticová, J. KříŽ, D. Kubies,

. 2020 ; 8 (2) : 631-647. [pub] 2020Jan21

Language English Country Great Britain

Document type Journal Article

Grant support
NV16-28254A MZ0 CEP Register

The effectiveness of cell transplantation can be improved by optimization of the transplantation site. For some types of cells that form highly oxygen-demanding tissue, e.g., pancreatic islets, a successful engraftment depends on immediate and sufficient blood supply. This critical point can be avoided when cells are transplanted into a bioengineered pre-vascularized cavity which can be formed using a polymer scaffold. In our study, we tested surface-modified poly(lactide-co-caprolactone) (PLCL) capsular scaffolds containing the pro-angiogenic factor VEGF. After each modification step (i.e., amination and heparinization), the surface properties and morphology of scaffolds were characterized by ATR-FTIR and XPS spectroscopy, and by SEM and AFM. All modifications preserved the gross capsule morphology and maintained the open pore structure. Optimized aminolysis conditions decreased the Mw of PLCL only up to 10% while generating a sufficient number of NH2 groups required for the covalent immobilization of heparin. The heparin layer served as a VEGF reservoir with an in vitro VEGF release for at least four weeks. In vivo studies revealed that to obtain highly vascularized PLCL capsules (a) the optimal VEGF dose for the capsule was 50 μg and (b) the implantation time was four weeks when implanted into the greater omentum of Lewis rats; dense fibrous tissue accompanied by vessels completely infiltrated the scaffold and created sparse granulation tissue within the internal cavity of the capsule. The prepared pre-vascularized pouch enabled the islet graft survival and functioning for at least 50 days after islet transplantation. The proposed construct can be used to create a reliable pre-vascularized pouch for cell transplantation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025261
003      
CZ-PrNML
005      
20220329145250.0
007      
ta
008      
201125s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1039/c9bm01280j $2 doi
035    __
$a (PubMed)31729495
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kasoju, Naresh $u Institute of Macromolecular Chemistry Czech Academy of Sciences, Heyrovsky sq.2, Prague 162 06, Czech Republic. kubies@imc.cas.cz.
245    10
$a Bioengineering a pre-vascularized pouch for subsequent islet transplantation using VEGF-loaded polylactide capsules / $c N. Kasoju, A. Pátíková, E. Wawrzynska, A. Vojtíšková, T. Sedlačík, M. Kumorek, O. Pop-Georgievski, E. Sticová, J. KříŽ, D. Kubies,
520    9_
$a The effectiveness of cell transplantation can be improved by optimization of the transplantation site. For some types of cells that form highly oxygen-demanding tissue, e.g., pancreatic islets, a successful engraftment depends on immediate and sufficient blood supply. This critical point can be avoided when cells are transplanted into a bioengineered pre-vascularized cavity which can be formed using a polymer scaffold. In our study, we tested surface-modified poly(lactide-co-caprolactone) (PLCL) capsular scaffolds containing the pro-angiogenic factor VEGF. After each modification step (i.e., amination and heparinization), the surface properties and morphology of scaffolds were characterized by ATR-FTIR and XPS spectroscopy, and by SEM and AFM. All modifications preserved the gross capsule morphology and maintained the open pore structure. Optimized aminolysis conditions decreased the Mw of PLCL only up to 10% while generating a sufficient number of NH2 groups required for the covalent immobilization of heparin. The heparin layer served as a VEGF reservoir with an in vitro VEGF release for at least four weeks. In vivo studies revealed that to obtain highly vascularized PLCL capsules (a) the optimal VEGF dose for the capsule was 50 μg and (b) the implantation time was four weeks when implanted into the greater omentum of Lewis rats; dense fibrous tissue accompanied by vessels completely infiltrated the scaffold and created sparse granulation tissue within the internal cavity of the capsule. The prepared pre-vascularized pouch enabled the islet graft survival and functioning for at least 50 days after islet transplantation. The proposed construct can be used to create a reliable pre-vascularized pouch for cell transplantation.
650    _2
$a zvířata $7 D000818
650    12
$a bioinženýrství $7 D057005
650    _2
$a krevní glukóza $x analýza $7 D001786
650    _2
$a tobolky $x chemie $x metabolismus $7 D002214
650    _2
$a experimentální diabetes mellitus $x chemicky indukované $x metabolismus $x patologie $7 D003921
650    _2
$a injekce intraperitoneální $7 D007274
650    12
$a transplantace Langerhansových ostrůvků $7 D016381
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a molekulární struktura $7 D015394
650    12
$a fyziologická neovaskularizace $7 D018919
650    _2
$a velikost částic $7 D010316
650    _2
$a polyestery $x chemie $x metabolismus $7 D011091
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani inbrední LEW $7 D011917
650    _2
$a streptozocin $x aplikace a dávkování $7 D013311
650    _2
$a vaskulární endoteliální růstové faktory $x chemie $x metabolismus $7 D042442
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pátíková, Alžběta, $d 1990- $7 xx0271325
700    1_
$a Wawrzynska, Edyta
700    1_
$a Vojtíšková, AlŽběta
700    1_
$a Sedlačík, Tomáš
700    1_
$a Kumorek, Marta
700    1_
$a Pop-Georgievski, Ognen
700    1_
$a Sticová, Eva
700    1_
$a KříŽ, Jan
700    1_
$a Kubies, Dana
773    0_
$w MED00191571 $t Biomaterials science $x 2047-4849 $g Roč. 8, č. 2 (2020), s. 631-647
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31729495 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20220329145246 $b ABA008
999    __
$a ok $b bmc $g 1599406 $s 1115947
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 8 $c 2 $d 631-647 $e 2020Jan21 $i 2047-4849 $m Biomaterials science $n Biomater Sci $x MED00191571
GRA    __
$a NV16-28254A $p MZ0
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...